Trial · NCT00083551
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
NCT00083551, Phase 3, Completed, University of Arkansas; results first posted 2015-09-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy. Trials, record NCT00083551. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00083551
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- NCT number
- NCT00083551
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 668 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- First posted
- 2004-05-27
- Last updated
- 2015-11-23
- Results first posted
- 2015-09-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | 6 Years | Overall Survival at six years after initiating protocol therapy |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | 6 Years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Thalidomide | 65 | percentage of participants | ||
| Overall Survival | No Thalidomide | 58 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Thalidomide | 323 | |
| Overall Study | STARTED | No Thalidomide | 345 | |
| Overall Study | COMPLETED | Thalidomide | 323 | |
| Overall Study | COMPLETED | No Thalidomide | 345 | |
| Overall Study | NOT COMPLETED | Thalidomide | 0 | |
| Overall Study | NOT COMPLETED | No Thalidomide | 0 |
Source ClinicalTrials.gov
Adverse events846
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Grade 1 Arrythmia, NOS | Cardiac disorders | Thalidomide | 70 | 323 | |
| other | Grade 1 Arrythmia, NOS | Cardiac disorders | No Thalidomide | 88 | 345 | |
| other | Grade 2 Arrythmia, NOS | Cardiac disorders | Thalidomide | 21 | 323 | |
| other | Grade 2 Arrythmia, NOS | Cardiac disorders | No Thalidomide | 29 | 345 | |
| other | Grade 1 Edema | Cardiac disorders | Thalidomide | 101 | 323 | |
| other | Grade 1 Edema | Cardiac disorders | No Thalidomide | 83 | 345 | |
| other | Grade 2 Edema | Cardiac disorders | Thalidomide | 33 | 323 | |
| other | Grade 2 Edema | Cardiac disorders | No Thalidomide | 28 | 345 | |
| other | Grade 1 Sinus tachycardia | Cardiac disorders | Thalidomide | 0 | 323 | |
| other | Grade 1 Sinus tachycardia | Cardiac disorders | No Thalidomide | 16 | 345 |
1 to 10 of 846Source ClinicalTrials.gov
See all 846 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Thalidomide | ||
| Total, all-cause mortality | No Thalidomide | ||
| Total, other adverse events | Thalidomide | 323 | 323 |
| Total, other adverse events | No Thalidomide | 345 | 345 |
| Total, serious adverse events | Thalidomide | 323 | 323 |
| Total, serious adverse events | No Thalidomide | 345 | 345 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Thalidomide vs No Thalidomide: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00083551
GET https://conductscience.org/api/trials/v1/NCT00083551/events?page=2